The International Osteoporosis Foundation (IOF)
One broken bone leads to another, warns IOF on World Osteoporosis Day
mehr
Storys zum Thema Medizin, Gesundheit
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Zentiva Reinforces Its Presence In Greece To Better Serve Greek People
Prague (ots/PRNewswire) - Zentiva reinforces its presence in Greece by signing a partnership with the company Lavipharm for representation, promotion, and distribution of its pharmaceutical products in Greece. With an established presence in Europe, Zentiva continues to strengthen its capabilities and service offering for people, by partnering with Lavipharm. "We are ...
mehrGalapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
Mechelen, Belgium and Paris (ots/PRNewswire) - Servier and Galapagos NV report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086. ROCCELLA is a global, double-blind, placebo-controlled, dose ranging trial evaluating the efficacy and safety of three ...
mehrNew Global Survey Raises Red Flags for Journalism in the COVID-19 Era
London (ots/PRNewswire) - Results launched today by International Center for Journalists (ICFJ) and Tow Center for Digital Journalism at Columbia University Facing everything from a barrage of disinformation to heightened security risks and a mental health crisis, journalists around the world are contending with myriad daunting challenges as they report on a deadly pandemic, according to the first results from a global ...
mehrMeet Zent2U at Virtual CPhi Festival of Pharma 2020
Prague (ots/PRNewswire) - The B2B Zent2U platform, powered by Zentiva, attends the online CPhI Festival of Pharma. The team will showcase its R&D pipeline assets for strategic partnerships through Zent2u. During this virtual congress, Zent2U representatives will meet with strategic stakeholders to discuss future collaboration leading to partnerships for success. "Building win-win partnerships is at the heart of our growth ...
mehrLamPORE test for SARS-CoV-2 detection gains CE-IVD mark
Oxford, England (ots/PRNewswire) - LamPORE is a new, rapid, scalable, accurate test, for the detection of the SARS-CoV-2 virus that causes COVID-19. LamPORE is designed to be performed on a desktop device, GridION, or a palm-sized device, MinION Mk1C. Following an application to the UK's MHRA, the LamPORE assay is now CE marked for in vitro diagnostic use for the detection of the SARS-CoV-2 virus, using the GridION ...
mehr
Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Thousand Oaks, Calif., South San Francisco, Calif., and Suresnes, France (ots/PRNewswire) - - Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events - Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death - Results Will Be Presented in Late Breaking ...
mehrThe HARMONY Alliance launches HARMONY PLUS, a new public-private partnership to improve outcomes for patients with blood cancers
The Hague, Netherlands (ots/PRNewswire) - - HARMONY PLUS builds upon the success of HARMONY in capitalizing on Big Data to speed up the development of more effective treatments for patients with blood cancers. - HARMONY PLUS will leverage the HARMONY Big Data Platform, a central data poolof anonymized data, ...
mehrMerck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis
Darmstadt, Germany (ots/PRNewswire) - - Merck out-licenses promising clinical-stage program to Novartis - Anti-ADAMTS5 Nanobody® programis Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain - Merck receives upfront payment of EUR 50 million with the potential of ...
mehrDebiopharm and the Japanese Cancer Association Announce Winners of the 2020 JCA-Mauvernay Award
Lausanne (ots) - For its sixteenth edition, the JCA-Mauvernay Award was awarded to Doctor Hideaki Ogiwara and Doctor Keisuke Kataoka Debiopharm (www.debiopharm.com), a Swiss-based global, biopharmaceutical company, presented the JCA-Mauvernay Award on October 3rd to Dr. Hideaki Ogiwara from the Division of Cancer Therapeutics of the National Cancer Center Research ...
mehrDEBIOPHARM LAUNCHES TRILYNX - A LARGE-SCALE PHASE III CLINICAL TRIAL TO FURTHER EVALUATE XEVINAPANT IN THE TREATMENT OF HEAD & NECK CANCER
Lausanne, Switzerland (ots) - First patient dosed in the randomized, placebo-controlled Phase III study of xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) Debiopharm (www.debiopharm.com), a ...
mehrSOPHiA GENETICS Raises $110 Million in Oversubscribed New Funding Round
Lausanne, Switzerland and Boston (ots/PRNewswire) - Supporting the Company's Global Expansion to Meet Growing Clinical and Biopharma Demand for Data-Driven Medicine - SOPHiA GENETICS enters next stage of its global expansion with oversubscribed Series F round exceeding $110 million, led by major health-tech fund and followed by strategic industry leader - Company ...
mehr
New Study: Postoperative Pain Can Be Reduced by Using NOL Monitoring to Guide Analgesic Medication During Surgery
Ramat Gan, Israel (ots/PRNewswire) - A new study has found that monitoring pain response levels during surgery with NOL technology (Medasense, Ramat Gan, Israel) can help reduce postoperative pain. Exploring the potential use of NOL monitoring to help enhance recovery after surgery, the study demonstrated that ...
mehrBiovision Foundation / A decade on: A critical new book by UN's World Agriculture Report (IAASTD) members calls for an accelerated transformation of our food systems
Zurich (ots/PRNewswire) - It is perfect timing: In mid-October the world will discuss the topic. A ground breaking book has been published today to support governments, NGOs and the wider public as they make vital choices that impact the future direction of food production across the globe. The book "Transformation ...
mehrBiovision Stiftung für ökologische Entwicklung
2Biovision Foundation / A decade on: a critical new book by UN's World Agriculture Report (IAASTD) members calls for an accelerated transformation of our food systems. It is perfect timing: in mid-October the world will discuss the topic
mehrHovione Announces Partnership to Support Manufacturing of Antiviral Veklury® for COVID-19
Lisbon, Portugal (ots/PRNewswire) - Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®. Captisol®, a Ligand product, is a chemically modified cyclodextrin proven to improve the solubility and stability of drugs. It is used in the formulation of Gilead's COVID-19 treatment Veklury® ...
mehrFDI World Dental Federation and Smile Train: Children with clefts are at high risk for tooth decay, gum disease and other serious oral health concerns
mehrJennewein Biotechnologie GmbH and Chr. Hansen A/S to join forces in high-growth Human Milk Oligosaccharides market
Rheinbreitbach and Bonn, Germany (ots/PRNewswire) - Jennewein Biotechnologie GmbH agreed to join forces with Chr. Hansen Holding A/S, a leading bioscience company based in Hoersholm/Denmark, to lead the global market for human milk oligosaccharides (HMOs). Chr. Hansen entered into an agreement to acquire all shares ...
mehr
DEBIOPHARM HONORED AS A 2020 SWISS BIOTECH SUCCESS STORY WINNER FOR OUTSTANDING ACHIEVEMENTS OVER 40 YEARS
Lausanne, Switzerland (ots) - Debiopharm, (www.debiopharm.com), a Swiss-based biopharmaceutical company today announced being one of the recipients of the 2020 Swiss Biotech Success Story Award for exceptional achievements in the biotech industry. Every year, the Swiss Biotech Association awards companies or ...
mehrDEBIOPHARM TO PRESENT LATE BREAKING HEAD & NECK CANCER ABSTRACT AT THE 2020 EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS
Lausanne, Switzerland (ots) - Debiopharm announces the presentation of the 3-year phase II follow-up data along with 2 posters for xevinapant (antagonist of IAP -Inhibitor of Apoptosis Proteins) and WEE1 inhibitor Debio 0123 Debiopharm, ...
Ein DokumentmehrMerck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020
Darmstadt, Germany (ots/PRNewswire) - · New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer · Overall efficacy data, and analyses of brain metastases and HRQoL for tepotinib? from ...
mehrNew MAVENCLAD® Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting Highlight Rapid Onset of Action and Compelling Post-Approval Safety
Darmstadt, Germany (ots/PRNewswire) - In MAGNIFY-MS, patients experienced a rapid onset of action from end of Month 1 that was significant in all study periods versus baseline Post-approval safety analysis showed no increased risk of viral respiratory infections and lower rates of malignancy than in the clinical ...
mehrTheratechnologies Announces Launch of Trogarzo® in Germany
Montreal (ots/PRNewswire) - First commercial launch in Europe Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Trogarzo® will be commercially available in Germany as of tomorrow through its subsidiary, Theratechnologies Europe Limited. Theratechnologies filed its health ...
mehrMerck Announces Positive Phase II Results for Investigational Sonelokinab (M1095) in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Sonelokinab is an investigational IL-17 A/F Nanobody®, which neutralizes both IL-17A and IL-17F - Phase II study was facilitated by Avillion as part of an innovative co-development model Merck, a leading science and technology company, ...
mehr
Belgian scale-up Oncomfort raises EUR10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation to further develop its Digital SedationTM through Virtual Reality
mehrTennis Champion Caroline Wozniacki and UCB Launch Advantage Hers Campaign for Women with Chronic Inflammatory Diseases
Brussels, Belgium (ots/PRNewswire) - - Grand Slam winner Caroline Wozniacki is the highest-ranking female athlete known to have been diagnosed with rheumatoid arthritis whilst still playing professional tennis - Advantage Hers will equip and empower women around the world living with chronic inflammatory diseases, ...
mehrFinal Phase II Results for UCB's Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances
Brussels (ots/PRNewswire) - - Phase II data demonstrated clinically meaningful platelet count increases with meaningful decreases in IgG concentration - Rozanolixizumab's subcutaneous route of administration shows potential to deliver targeted individualized patient care for people living with Primary Immune ...
mehrZur Rose and KPT together launch digital medicines assistant Medi+
mehrAl-Jadaan: Reopening of the Economy, Saudi Shows Positive Results
Riyadh, Saudi Arabia (ots/PRNewswire) - Euromoney Saudi Digital Series 2020 At the 15th virtual edition of the Euromoney Saudi Arabia Conference HE Mr. Mohammed Al-Jadaan, Minister of Finance and Acting Minister of Economy and Planning stated that the Saudi economy is recovering, in arguably the most challenging of years for a century. Saudi Arabia ended 2019 with ...
mehrMerck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Company to present 54 abstracts across its MS portfolio - MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib - New long-term data and real-world evidence further characterise efficacy and safety ...
mehr
Vorherige17181920212223242526Nächste